Open Access Articles- Top Results for Conivaptan


Skeletal formula of conivaptan
Space-filling model of conivaptan
Systematic (IUPAC) name
N-(4-((4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin- 6(1H)-yl)carbonyl)phenyl)- (1,1'-biphenyl)-2-carboxamide
Clinical data
Trade names Vaprisol
AHFS/ monograph
  • US: C (Risk not ruled out)
Pharmacokinetic data
Bioavailability N/A
210101-16-9 7pxY
PubChem CID 151171
IUPHAR ligand 2203
DrugBank DB00872 7pxY
ChemSpider 133239 7pxY
UNII 0NJ98Y462X 7pxY
KEGG D01236 7pxN
ChEBI CHEBI:681850 7pxY
Chemical data
Formula C32H26N4O2
498.583 g/mol
 14pxN (what is this?)  (verify)

Conivaptan (YM 087, brand name Vaprisol) is a non-peptide inhibitor of antidiuretic hormone (vasopressin receptor antagonist). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH), and there is some evidence it may be effective in heart failure. It is marketed by Cumberland Pharmaceuticals, Inc.

Conivaptan inhibits two of the three subtypes of the vasopressin receptor (V1a and V2). Effectively, it causes iatrogenic nephrogenic diabetes insipidus.

Conivaptan has not been approved by the FDA for the treatment of decompensated congestive heart failure. However, in theory, vasopressin receptor antagonism would be particularly useful in this setting, and an initial study shows that it has some promise.[1]


Lua error in package.lua at line 80: module 'Module:Buffer' not found. Lua error in package.lua at line 80: module 'Module:Buffer' not found.